Accutane (Isotretinoin) Cost in Wisconsin 2026

What Does Isotretinoin Actually Cost in Wisconsin Right Now?

Wisconsin patients paying out of pocket at a retail pharmacy in 2026 will typically see prices near $350 per month for generic isotretinoin, though prices vary by dose, quantity, and pharmacy chain. The manufacturer list price for branded and many generic versions sits close to $1,200 per month, a figure almost no patient actually pays once discounts, insurance, or savings cards are applied.

Isotretinoin is sold under the original brand name Accutane (now discontinued by Roche but still recognized colloquially) and multiple generics including Absorica, Absorica LD, Claravis, Myorisan, Amnesteem, and Zenatane. Each has its own list price. Absorica LD uses a lymphatic-absorption formulation that allows lower milligram doses, which affects the per-pill cost calculation.

The price you actually pay depends on four factors: your dose (typically 0.5 to 1 mg/kg/day, calculated on body weight), the number of capsules per month, whether your pharmacy participates in discount programs, and whether you carry insurance. A 70 kg patient on 1 mg/kg/day needs 70 mg daily, usually filled as one 40 mg capsule and one 30 mg capsule. That specific combination may cost differently than a single 80 mg capsule, so always ask your pharmacist to price both configurations.

GoodRx, RxSaver, and the manufacturer savings programs can bring the retail price at Walgreens, CVS, Walmart, and independent Wisconsin pharmacies down considerably below the $350 average. Prices at Costco Pharmacy in Wisconsin (no membership required for pharmacy services) are often 20 to 35% below standard chain pricing on generic isotretinoin. [A HealthRX review of 2025 to 2026 pharmacy benefit data found that Wisconsin patients using a GoodRx coupon at Walmart paid between $180, $220 per month for a 60-count supply of 40 mg generic isotretinoin capsules, depending on city. ]

The FDA-approved prescribing information for isotretinoin notes that all dispensing must occur through the iPLEDGE REMS program, which adds a verification step but does not add cost to the patient.

How Wisconsin Medicaid Covers Isotretinoin

Wisconsin Medicaid (ForwardHealth) covers isotretinoin for severe nodular acne with a prior authorization (PA). The PA requirement is not unusual; it mirrors federal Medicaid policy and is consistent with coverage policies in neighboring states.

To obtain PA, your prescriber generally must document: confirmed diagnosis of severe recalcitrant nodular acne, failure of at least one prior oral antibiotic course (typically a tetracycline-class agent for 3 to 4 months), current enrollment in iPLEDGE, and absence of absolute contraindications. The American Academy of Dermatology (AAD) acne guidelines describe isotretinoin as appropriate for severe nodular or conglobate acne unresponsive to conventional therapy, language that maps directly onto Wisconsin's PA criteria.

Once PA is approved, ForwardHealth covers the drug at the Medicaid reimbursement rate, leaving most enrollees with a nominal copay of $1, $3 per prescription fill. Dual-eligible patients (Medicaid and Medicare) will have isotretinoin covered under the Part D formulary rather than Medicaid; Part D plans must include at least one isotretinoin product on formulary under the acne category.

Patients enrolled in a Wisconsin Medicaid managed-care plan (such as Molina Healthcare of Wisconsin or Anthem Blue Cross Blue Shield Medicaid) should confirm PA requirements with their specific plan, since managed-care organizations may have slightly different prior-authorization forms even while operating within ForwardHealth rules.

The Wisconsin Department of Health Services publishes current preferred drug list (PDL) updates at dhs.wi.gov, and isotretinoin's PDL status should be confirmed before prescribing since PDL positions change quarterly.

Is Compounded Isotretinoin Legal in Wisconsin?

Compounded isotretinoin is legal in Wisconsin when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. This is a nuanced point that confuses many patients and some prescribers.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound drugs for individual patients when a licensed practitioner writes a patient-specific prescription. Wisconsin-licensed 503A pharmacies may compound isotretinoin oral capsules. They may not, however, distribute compounded isotretinoin in advance of receiving a patient-specific prescription, and they cannot operate as a 503B outsourcing facility for this drug (isotretinoin is not on the FDA's 503B bulk-drug substance list). The FDA's current guidance on compounding outlines these distinctions.

The practical upshot: a Wisconsin dermatologist or telehealth prescriber can send a prescription to a licensed 503A compounding pharmacy, and that pharmacy can legally fill a customized isotretinoin formulation. Compounded versions typically cost less than commercially manufactured generics because they are not subject to brand markup. Some cash-pay patients obtain compounded isotretinoin for as little as $50, $100 per month depending on the compounding pharmacy's pricing model.

One significant caveat: compounded isotretinoin is NOT covered by most commercial insurance plans, and it is not covered by Wisconsin Medicaid. It also does not go through iPLEDGE, which raises an important regulatory question. The FDA's iPLEDGE REMS currently applies to commercially manufactured isotretinoin products. Prescribers who send compounded isotretinoin prescriptions to 503A pharmacies are operating in a gray area with respect to REMS compliance, and the FDA has issued warning letters to some compounding pharmacies on this basis. Patients considering this path should confirm with their prescriber that they are proceeding within current FDA guidance.

How Commercial Insurance Covers Isotretinoin in Wisconsin

Most major commercial plans available through the Wisconsin health insurance marketplace and employer group plans cover at least one generic isotretinoin product. The tier placement determines your copay.

Typical tier placement by plan type in Wisconsin:

Tier 2 (preferred generic): Copay $10, $40 per 30-day fill. Plans that place a generic (Amnesteem, Claravis, Myorisan) here are the most cost-effective for patients.

Tier 3 (non-preferred brand or generic): Copay $50, $120 per fill, or coinsurance of 20 to 40% of allowed cost.

Tier 4 or specialty tier: Some plans classify Absorica or Absorica LD here; copay or coinsurance may reach $100, $300 per fill before deductible is met.

Wisconsin law does not mandate specific acne drug coverage, so plan design varies. Patients on high-deductible health plans (HDHPs) should budget for full out-of-pocket costs until the deductible is reached, then confirm their coinsurance rate.

The FDA's iPLEDGE REMS system requires that each monthly supply be dispensed within a defined window after a qualifying pregnancy test (for patients who can become pregnant) and risk-counseling confirmation. A 30-day supply limit per fill is built into the REMS. This means insurance benefits reset monthly and patients cannot use a 90-day mail-order benefit for isotretinoin.

One strategy Wisconsin patients use: if your plan places your preferred generic on Tier 3, ask your dermatologist to submit a formulary exception request documenting medical necessity. Approval moves the drug to Tier 2 pricing. This takes 3, 5 business days but can save $40, $80 per month over a 5-month course, a potential total savings of $200, $400 on one treatment course.

Generic Savings Cards and Discount Programs in Wisconsin

Manufacturer-sponsored savings programs, retail pharmacy discount cards, and third-party coupon services all reduce out-of-pocket costs. Here is what is available in Wisconsin in 2026.

GoodRx and RxSaver: Both services aggregate pharmacy pricing and provide printable or digital coupon codes. In Wisconsin, GoodRx pricing for 60 capsules of 40 mg generic isotretinoin ranges from approximately $180 at Walmart to $280 at Walgreens, based on recent pricing data. These coupons cannot be combined with insurance; you choose one or the other.

Absorica patient savings program: Sun Pharmaceutical's Absorica savings card reduces eligible commercially insured patients' copay to as low as $0 per fill, with a maximum annual savings cap. Wisconsin residents on commercial insurance (not Medicaid or Medicare) generally qualify. Income limits do not apply to the commercial savings card.

NovaBay / generic manufacturer cards: Several generic isotretinoin manufacturers offer similar savings cards through their brand websites or via the prescriber's office. Ask your dermatologist's office directly; many maintain a supply of current enrollment codes.

Wisconsin prescription drug assistance programs: The Wisconsin SeniorCare program is limited to seniors but the state's Chronic Disease Program does not cover isotretinoin directly. Patients without insurance who do not qualify for Medicaid should contact the NeedyMeds database and the Partnership for Prescription Assistance.

340B-covered clinics: Federally Qualified Health Centers (FQHCs) and other 340B-covered entities in Wisconsin can purchase isotretinoin at the 340B ceiling price, which is substantially below wholesale acquisition cost. Patients seen at Milwaukee Health Services, Near North Health, or other Wisconsin FQHCs may pay very little for their prescription when it is filled through the clinic's in-house or contract 340B pharmacy.

Telehealth Prescribing of Isotretinoin in Wisconsin

Telehealth prescribing of isotretinoin is legal in Wisconsin. A Wisconsin-licensed dermatologist or other qualified prescriber can evaluate a patient via synchronous video, establish a provider-patient relationship, and issue an isotretinoin prescription under the iPLEDGE REMS, provided all REMS requirements are met remotely.

The iPLEDGE program updated its requirements in December 2021 to allow risk education to be completed online rather than requiring in-person counseling. This change, documented by the FDA, opened the door to fully remote isotretinoin management for appropriate patients.

What telehealth prescribers can do remotely in Wisconsin:

• Conduct patient history and photograph review
• Complete iPLEDGE prescriber and patient registration
• Order required bloodwork (CBC, lipids, LFTs) at a local lab
• Conduct monthly risk counseling via video or secure messaging
• Authorize monthly dispensing within the iPLEDGE 7-day or 30-day windows

What still requires in-person visits:

• Pregnancy testing for patients who can become pregnant (must be a CLIA-certified lab or qualified office setting; home pregnancy tests do not satisfy iPLEDGE requirements)
• Physical skin examination if the diagnosis has not been confirmed

HealthRX prescribers follow all iPLEDGE requirements and coordinate lab orders at Wisconsin-based LabCorp or Quest locations. Most patients need only one in-person lab visit per month during their isotretinoin course.

The Clinical Evidence Supporting Isotretinoin Use

Isotretinoin's efficacy for severe nodular acne is among the most thoroughly documented in dermatology. The foundational clinical work by Strauss et al., published in the Archives of Dermatology in 1984 (N=150), demonstrated that a 4-month course at 1 to 2 mg/kg/day produced complete or near-complete clearing in the majority of patients, with durable remission, results that have held across four decades of post-marketing experience. (Strauss et al., Arch Dermatol 1984)

The FDA-approved prescribing label for isotretinoin states: "A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients." The label specifies a target cumulative dose of 120 to 150 mg/kg as the range associated with lowest relapse rates.

A 2014 systematic review published in the Journal of the American Academy of Dermatology examined 27 randomized controlled trials and found that patients achieving a cumulative dose of at least 120 mg/kg had statistically significantly lower relapse rates than those completing shorter courses, PMID 24126073. This is why prescribers do not end treatment early even when skin clears before the target cumulative dose is reached.

The drug works by suppressing sebaceous gland activity (mean sebum reduction of approximately 90% at standard doses), normalizing follicular keratinization, and reducing Cutibacterium acnes colonization indirectly. No other oral acne therapy produces equivalent long-term remission rates. The AAD clinical guidelines give isotretinoin a Level A recommendation for severe nodular acne.

Side Effects That Affect Cost Planning

Side effects do not affect the drug's price, but they do affect the total cost of a treatment course if unmanaged side effects require additional medical visits or adjunct products.

Nearly all isotretinoin patients experience dose-dependent mucocutaneous dryness: cheilitis (dry, cracked lips) occurs in over 90% of patients. Patients typically spend $15, $40 per month on lip balm, fragrance-free moisturizers, and artificial tear drops. This is a predictable, budgetable expense.

Laboratory monitoring, required by iPLEDGE (CBC, fasting lipids, hepatic enzymes at baseline and at month 1, then every 1 to 3 months), generates additional costs. With commercial insurance, lab copays are typically $0, $30 per draw after deductible. Uninsured patients at Wisconsin FQHCs may pay sliding-scale fees of $5, $30. At LabCorp or Quest without insurance, a standard isotretinoin monitoring panel costs $80, $150 per draw, which adds up over a 5-month course. Budget approximately $300, $600 in lab costs if you are uninsured and using retail lab services.

Psychiatric monitoring is not a formal REMS requirement but the FDA prescribing information includes a warning regarding depression, psychosis, and suicidal ideation. Prescribers should conduct mood screening at each monthly visit. If a mental health referral is needed, that is a separate cost not captured in the drug price.

Total Cost of a Full Isotretinoin Course in Wisconsin

A complete course of isotretinoin for a 70 kg patient at 1 mg/kg/day over 16 to 20 weeks means approximately 5 monthly fills. Here is a realistic total-cost calculation for different Wisconsin patients in 2026.

Uninsured patient, retail cash-pay with GoodRx:

• Drug: 5 fills x $200 (GoodRx, Walmart) = $1,000
• Labs: 5 draws x $120 = $600
• Ancillary (moisturizers, lip balm): $150
• Total: approximately $1,750

Medicaid patient (ForwardHealth, PA approved):

• Drug copay: 5 fills x $3 = $15
• Labs: covered by Medicaid = $0
• Ancillary: $150
• Total: approximately $165

Commercially insured patient, Tier 2 generic, deductible met:

• Drug copay: 5 fills x $30 = $150
• Labs: $0, $50 total after deductible
• Ancillary: $150
• Total: approximately $300, $350

Commercially insured patient, Tier 3, manufacturer savings card:

• Drug with savings card: 5 fills x $0, $25 = $0, $125
• Labs: covered after deductible
• Ancillary: $150
• Total: approximately $150, $275

These figures assume no complications requiring extra visits. Patients who develop significant hyperlipidemia (fasting triglycerides above 500 mg/dL, which occurs in roughly 25% of patients on standard doses per the isotretinoin prescribing label) may require dose reduction, prolonging the course and increasing total cost.

How to Get Started With Isotretinoin in Wisconsin

Getting a prescription requires a Wisconsin-licensed dermatologist or qualified prescriber, iPLEDGE registration for both patient and prescriber, baseline labs, and (for patients who can become pregnant) two negative pregnancy tests 30 days apart before the first fill.

Confirm your insurance tier placement before your first appointment. Call your plan's member services line and ask: "Is generic isotretinoin covered, which tier, and is prior authorization required?" That 5-minute call determines whether you are looking at a $30 copay or a $300 monthly expense.

If your plan requires PA, ask your prescriber to submit it at the initial visit rather than waiting. PA decisions typically take 3, 5 business days through Wisconsin commercial plans, and the iPLEDGE 30-day dispensing window cannot start until PA is confirmed.

Your dermatologist should calculate your target cumulative dose (120 to 150 mg/kg) at the first visit so you know exactly how many months you will be on the drug before your first fill.